<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791787</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20200230H</org_study_id>
    <nct_id>NCT04791787</nct_id>
  </id_info>
  <brief_title>Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes</brief_title>
  <official_title>Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes CTMS 20-0042</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team will examine the effect of a ketogenic diet alone and ketogenic diet&#xD;
      supplemented with oral ketones on how the body of individuals with type 2 diabetes respond to&#xD;
      insulin, regulates insulin secretion, food intake and energetic pathways and influences body&#xD;
      fat distribution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized into three groups (1) standard, weight maintaining diet&#xD;
      containing approximately 25-35% protein, 45-55% carbohydrate, 20-30% fat; (2) weight&#xD;
      maintaining isocaloric ketogenic diet containing approximately 15-25% protein, 5-10%&#xD;
      carbohydrate, 70-80% fat; (3) weight maintaining isocaloric diet containing approximately&#xD;
      15-25% protein, 5-10% carbohydrate, 70-80% fat supplemented with the ketone ester of&#xD;
      beta-hydroxy butyrate, 8 grams every 8 hours to further increase the plasma ketone&#xD;
      concentration by ~3 mM. Subjects will be further randomized on the basis of:&#xD;
&#xD;
      (i) HbA1c 7.0-8.5% and 8.5-10.5% to ensure similar baseline levels of glucose control and&#xD;
      (ii) drug na√Øve versus drug-treated. At the time of screening, after a 10-12 hour overnight&#xD;
      fast, indirect calorimetry will be performed with a ventilated hood system for 60 minutes to&#xD;
      measure baseline energy expenditure. An initial weight maintenance energy requirement&#xD;
      estimate as 1.5 times resting energy expenditure (obtained by indirect calorimetry) will be&#xD;
      started. Diets will consist of a 10-day rotating menu using NutriAdmin for meal planning and&#xD;
      Nutrition Maker for analysis of recipes Food will be prepared in the Cafeteria and or the&#xD;
      Metabolic Kitchen at the Texas Diabetes Institute and certified by a dietician. Subjects will&#xD;
      report to the diet kitchen at 8 AM on Monday through Saturday where they will eat their&#xD;
      breakfast and pick up food for their lunch and dinner. On Saturday, participants also will be&#xD;
      given food for their Sunday meals. Subjects will maintain a daily dietary log with all food&#xD;
      consumed. On each visit subjects will be weighed; dietary log will be reviewed and the&#xD;
      caloric content of the diet will be adjusted to maintain the body weight constant. Blood&#xD;
      pressure will be measured in the reclining position x 2 separate days. Antidiabetic&#xD;
      medications will not be changed during the study unless hypoglycemia (fasting plasma glucose&#xD;
      &lt;70 mg/dl or symptoms) occurs. The study duration will be 10 days which should be sufficient&#xD;
      to observe the effect of hyperketonemia on glucose/lipid metabolism and energy expenditure.&#xD;
      If participant cannot come on the last days of his/her diet treatment, than we will extend&#xD;
      this period up to 13 days and participant will be given diet for additional days till&#xD;
      completion of the study visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized into 3 groups. Each group will be assigned to one of 4 arms.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>A change in FPG will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Glucose production (HGP)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change of hepatic glucose production will be measured using 3H-glucose infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Body Fat Oxidation</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in whole body fat oxidation will be measured using indirect calorimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Fat</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in whole body fat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Fat Content</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in hepatic fat content</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in plasma insulin will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in C-peptide will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acid (FFA)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in FFA will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycerol level</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in Glycerol level will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoproteins (LDL)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoproteins (HDL)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in HDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Microalbumin excretion</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in urine microalbumin excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin test (HbA1c)</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine level</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>Change in fructosamine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glucose Metabolism Disorders (Including Diabetes Mellitus)</condition>
  <condition>Energy Supply; Deficiency</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard Weight Maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocaloric Diet with Beta-hydroxy butyrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard weight maintaining diet</intervention_name>
    <description>Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat</description>
    <arm_group_label>Standard Weight Maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Weight maintaining isocaloric ketogenic diet</intervention_name>
    <description>Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Isocaloric Diet with Beta-hydroxy butyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-hydroxy butyrate</intervention_name>
    <description>A supplement of ketone ester of beta-hydroxy butyrate</description>
    <arm_group_label>Isocaloric Diet with Beta-hydroxy butyrate</arm_group_label>
    <other_name>BHOB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18-70 years&#xD;
&#xD;
          2. BMI = 27.5-42 kg.m2&#xD;
&#xD;
          3. HbA1c = 7.0-10.5&#xD;
&#xD;
          4. Weight stable (¬±4-5lb) in the preceding 3 months&#xD;
&#xD;
          5. Good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of medications that affect glucose tolerance other than&#xD;
             metformin/sulfonylurea/DPP4 Inhibitor&#xD;
&#xD;
          2. Major organ disease&#xD;
&#xD;
          3. Estimated Glomerular filtration rate (eGFR) &lt;60 ml/min&#xD;
&#xD;
          4. Type 1 diabetes&#xD;
&#xD;
          5. Hematocrit &lt; 34 (if HbA1c is in the 8.5 to 10% range)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugenio Cersosimo, MD</last_name>
    <phone>210-358-7200</phone>
    <email>cersosimo@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Systems-Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Merovci, MD, MPH</last_name>
      <phone>210-567-5790</phone>
      <email>merovci@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Hansis-Diarte, MPH</last_name>
      <phone>210-567-3208</phone>
      <email>hansisdiarte@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph DeFronzo, MD</last_name>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Hansis-Diarte, MPH</last_name>
      <phone>210-567-3208</phone>
      <email>hansisdiarte@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketogenic diet</keyword>
  <keyword>Body fat</keyword>
  <keyword>Insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information will be shared as summary results on ClinicalTrials.gov and in a peer-reviewed scientific journal publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

